Acquista crypto Mercati Spot FuturesGOLD Earn Centro eventi

Altro

Soligenix announces HyBryte outperforms Valchlor in CTCL study with 60% treatment success and no adverse events. Read about this breakthrough in oncology therapySoligenix announces HyBryte outperforms Valchlor in CTCL study with 60% treatment success and no adverse events. Read about this breakthrough in oncology therapy

Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in CTCL Treatment Study

Autore: Citybuzz

Fonte: Citybuzz

2026/04/03 03:30

2 min di lettura

Per feedback o dubbi su questo contenuto, contattateci all'indirizzo [email protected].

Soligenix announced the publication of positive results from its comparability study evaluating HyBryte versus Valchlor for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy. The study revealed that after 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte. In contrast, Valchlor patients experienced multiple adverse reactions during the study period.

The findings support HyBryte’s potential as a well-tolerated therapy for early-stage CTCL, a rare form of non-Hodgkin lymphoma that affects the skin. The company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for CTCL treatment. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

Development programs in this business segment also include expansion of synthetic hypericin into psoriasis, as well as the company’s first-in-class innate defense regulator technology for inflammatory diseases. The company’s Public Health Solutions business segment includes development programs for vaccine candidates targeting various infectious diseases, supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.

The full study results are available in the publication, and additional information about the company’s research can be found through their corporate communications. The latest news and updates relating to Soligenix are available through various financial information platforms that track pharmaceutical developments.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in CTCL Treatment Study.

The post Soligenix’s HyBryte Shows Superior Efficacy and Safety Over Valchlor in CTCL Treatment Study appeared first on citybuzz.

Don't Miss $200,000 U-Fest

Get mystery boxes, 12% APR & $200 new user gifts!

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta [email protected] per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.